Wugen nabs $172M to advance memory NK cell platform

By The Science Advisory Board staff writers

July 15, 2021 -- Wugen announced it has raised $172 million to support further development of its NK cell platform and to continue ongoing trials for patients with severe acute myelogenous leukemia (AML).

In an ongoing phase I/II trial, WU-NK-101, the company's lead product, demonstrated an impressive complete response rate in relapsed/refractory AML, Wugen said. The company will also apply proceeds to advance its broader pipeline of next-generation products, including an allogeneic CD7-targeted CAR T cell therapy to treat T-cell leukemia and lymphoma.

The round of series B funding was co-led by Abingworth and Tybourne Capital Management.


Copyright © 2021 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.